Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the weight loss drugs, according to a new report.

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program could run into problems with voluntary participation and concerns about expense.